ArticleDiabetes, obesity & metabolism2021

Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.

Qiuhe Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.